Herbert Galang

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND There is no known reason to suspect an adverse drug interaction between dolutegravir-based antiretroviral therapy and sofosbuvir, simeprevir, or ledipasvir. There is a paucity of clinical data for this combination. METHODS Prospective, open-label study of patients with HIV well controlled on dolutegravir, abacavir, and lamivudine, who were(More)
  • 1